Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

TxCell (France), a clinical-stage biotechnology developing cell-based immunotherapies for chronic inflammatory and neurological diseases, closed a $15.9M Series C financing. Participants include CDC Entreprises, Auriga Partners and Seventure Partners. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP […]

Arteaus Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on antibody treatment for the prevention of migraine headache, closed a $18M Series A financing. Participants include Atlas Venture and OrbiMed.

PharmacoFore (San Carlos, CA) a clinical-stage biopharmaceutical company focused on improvement of existing drugs preventing misuse, abuse, and overdose of prescription medications for pain, closed a $10M Series A financing. Participants include Founders Fund.

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital. _________________________________________________________________________ NOTE: New OnBioVC Friday feature coming, well…this Friday!

Neuraltus Pharmaceuticals (Menlo Park, CA) a preclinical-stage developer of small-molecule drugs focused on Amyotropic Lateral Sclerosis and dyskinesia, closed a $17M Series A financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.

Synosia Therapeutics (Switzerland) develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology, closed a $28.7M Series B financing. Participants include Aravis Venture, Investor Growth Capital, Swiss Helvetia Fund, Versant Ventures, Abingworth, Novo A/S and 5am Ventures.

Link Medicine (Cambridge, MA) development-stage company focused on the treatment of several neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis, closed a $40M Series C financing. Participants include Clarus Ventures and SV Life Sciences.

Sierra Neuropharmaceuticals (Aurora, CO) development-stage biopharmaceutical company specializing treating neurological disorders, closed a $21.5M Series A financing. Participants include HealthCare Ventures, Morgenthaler Ventures, Sequel Ventures and High Country Venture.

PhysioSonics (Seattle, WA) a developer of noninvasive neurologic products, closed a $4M Series A financing. Participants include Johnson & Johnson Development Corp.

MindFrame (Lake Forrest, CA) developer of devices for ischemic stroke treatment, closed a $6M Series A financing. Participants include SV Life Sciences and Intersect Partners.

Capnia (Palo Alto, CA) development-stage company focused on therapeutic products using a medical gas delivery system, closed a $19.2M Series C financing. Participants include Asset Management, Vivo Ventures and Teknoinvest.

« Previous Entries  Next Page »

to top of page...